Takeda Pharmaceutical Company Limited Increase Decrease In Contingent Liabilities Recognised In Business Combination
Takeda Pharmaceutical Company Limited (TAK) reported Increase Decrease In Contingent Liabilities Recognised In Business Combination of -JPY 490.00 million for the 12-month period ending 2022-03-31, per its 20-F filed 2022-06-29.
Discontinued › Notes
ifrs-full:IncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination · last filed 2022-06-29
| Period end | Increase Decrease In Contingent Liabilities Recognised In Business Combination 12 month |
|---|---|
| 2022-03-31 | -490.00M JPY 20-F · filed 2022-06-29 |
| 2021-03-31 | -3.60B JPY 20-F · filed 2022-06-29 |
| 2020-03-31 | -4.64B JPY 20-F · filed 2022-06-29 |
| 2019-03-31 | -3.74B JPY 20-F · filed 2021-06-29 |
| 2018-03-31 | -2.26B JPY 20-F · filed 2020-06-24 |
| 2017-03-31 | -3.69B JPY 20-F · filed 2019-06-27 |